MD Anderson, AbbVie connect to advance cancer immunotherapy
The immunotherapy platform at Â鶹ӳ» MD Anderson Cancer Center and the global biopharmaceutical company AbbVie will join forces to find new ways to unleash the immune system’s potential to fight cancer.
The three-year collaboration agreement provides a framework for MD Anderson and AbbVie to efficiently choose and carry out preclinical and clinical studies evaluating new ideas in the cutting-edge area of immuno-oncology...
MD Anderson Applauds State of the Union Call to Cure Cancer
Â鶹ӳ» MD Anderson Cancer Center is grateful Vice President Joe Biden has inspired the creation of a national cancer moonshot...
Study reveals potential therapy targets for triple-negative breast cancer
In cancer, cell signaling pathways are the critical chain of events that can either quash or quicken disease progression.
A multi-institutional...